Stratagene and Merck Subsidiary, Rosetta Inpharmatics, enter into joint development and license agreement
Development of RNA Purification System for Use in Molecular Diagnostics and Research Applications
Stratagene Corporation has entered into a joint development and license agreement with Rosetta Inpharmatics LLC, a wholly-owned subsidiary of Merck & Co., Inc., to create an automated solution for the isolation of nucleic acids from a variety of clinical samples. Nucleic acid purification allows researchers to separate RNA contained in biological samples. Clinicians and researchers can use the purified RNA to perform gene expression analysis and other functions within molecular diagnostics.
Under the terms of the agreement, Stratagene and Rosetta will jointly develop a proprietary instrument and a single-use consumable that will be manufactured and commercialized by Stratagene. These products will be sold to Stratagene's current customer base and companies engaged in pharmacogenomics. Financial terms of the agreement were not disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
QIAGEN acquires Corbett Life Science - Transaction adds proprietary Real-Time PCR detection technologies to QIAGEN's portfolio of molecular testing solutions
NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer NOX-H94 - Anemia of Chronic Disease Study is Fourth Phase II Initiated by NOXXON in 2012
Allergy potential of strawberries and tomatoes depends on the variety
Kombucha to kimchi: Which fermented foods are best for your brain?
Biotype GmbH - Dresden, Germany
Improve patient outcomes in oncology
Aquapharm and Dundee University Sign Research Collaboration to find Marine Compounds to target Alzheimer’s
Epigenomics AG Successfully Validates Lung Cancer Test in Clinical Trial
